Applied DNA Sciences, Inc. (APDN)
After hours:
| Previous Close | 1.4800 |
| Open | 1.4800 |
| Bid | 1.7000 x 900 |
| Ask | 1.7200 x 2900 |
| Day's Range | 1.4800 - 1.7100 |
| 52 Week Range | 0.6200 - 7.3500 |
| Volume | |
| Avg. Volume | 138,076 |
| Market Cap | 21.944M |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9060 |
| Earnings Date | Feb 09, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Business Wire
Applied DNA to Report First Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, February 9, 2023
STONY BROOK, N.Y., February 02, 2023--Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that it will release financial results for the three months ended December 31, 2022, after the market closes on Thursday, February 9, 2023. The Company will host a conference call for the investment community to discuss its results and answer questions at 4:30 p.m. ET.
- Business Wire
Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines
STONY BROOK, N.Y., January 05, 2023--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development. The study, titled ‘A linear DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain elicits protective immunity in domestic cats,’ supports the further development of the Company’s LinearDNA™ platform for the large-scale enzyma
- Simply Wall St.
Applied DNA Sciences Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
Applied DNA Sciences ( NASDAQ:APDN ) Full Year 2022 Results Key Financial Results Revenue: US$18.2m (up 101% from FY...
